Literature DB >> 2646391

Bartter's syndrome--treatment with potassium, spironolactone and ACE-inhibitor.

P Clementsen1, A Høegholm, C L Hansen, M Damkjaer, P Christensen, J Giese.   

Abstract

The treatment of Bartter's syndrome is fraught with difficulties, and there is no consensus concerning the pathogenetic mechanisms involved. Potassium depletion with hypokaliaemia is a dominant feature of the syndrome. In this case history, a 42-year-old woman suffering from Bartter's syndrome did not improve on several therapeutic trials. An impressive progress was noted, however, after intensive potassium repletion with subsequent potassium/spironolactone/ACE-inhibitor treatment. After 24 months her condition was unchanged with normal and stable Se-potassium concentration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646391     DOI: 10.1111/j.1365-2796.1989.tb00048.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  2 in total

1.  Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter's syndrome.

Authors:  P Jest; K E Pedersen; N A Klitgaard; N Thomsen; K Kjaer; E Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Neonatal Bartter syndrome associated with ileal atresia and cystic fibrosis.

Authors:  A O Akuma; S K Mittal; A A Sambo
Journal:  Indian J Nephrol       Date:  2013-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.